Last reviewed · How we verify
Hympavzi (Marstacimab-Hncq)
Hympavzi (generic name: Marstacimab-Hncq) is a Tissue Factor Pathway Inhibitor (TFPI) Antagonist Monoclonal antibody drug developed by Pfizer Inc.. It is currently FDA-approved for Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation.
Hympavzi is a monoclonal antibody that targets tissue factor pathway inhibitor, and it is being studied in clinical trials for the treatment of Hemophilia A or B.
At a glance
| Generic name | Marstacimab-Hncq |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Tissue Factor Pathway Inhibitor (TFPI) Antagonist |
| Target | Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2) |
| Modality | Monoclonal antibody |
| Therapeutic area | Rare Disease |
| Phase | FDA-approved |
Mechanism of action
Marstacimab-hncq is a human monoclonal IgG1 antibody that binds to and neutralizes TFPI, the primary inhibitor of the extrinsic coagulation cascade. By blocking TFPI activity, the drug enhances thrombin generation within the extrinsic pathway of coagulation. TFPI normally inactivates the protease functions of the FXa/FVIIa/TF complex by binding to and inhibiting the factor Xa active site via its second Kunitz inhibitor domain (K2), which is the specific target of marstacimab-hncq.
Approved indications
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors
Common side effects
- Injection site reaction
- Headache
- Pruritus
Serious adverse events
- Venous thrombosis
- Peripheral swelling
Drug interactions
- Standard coagulation measures (aPTT and PT)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hympavzi CI brief — competitive landscape report
- Hympavzi updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Hympavzi
What is Hympavzi?
How does Hympavzi work?
What is Hympavzi used for?
Who makes Hympavzi?
What is the generic name of Hympavzi?
What drug class is Hympavzi in?
What development phase is Hympavzi in?
What are the side effects of Hympavzi?
What does Hympavzi target?
Related
- Drug class: All Tissue Factor Pathway Inhibitor (TFPI) Antagonist drugs
- Target: All drugs targeting Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Rare Disease
- Indication: Drugs for Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors
- Indication: Drugs for Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing